an increase in sales. In addition, products, such as   VESIcare, and Lexiscan, a pharmacologic stress agent,  continuously grew. Also, income from anticancer drug  Tarceva increased. Sales of Prograf fell due to the impact  of generics. BETMIGA and XTANDI, which were launched in February  and July 2013, respectively, contributed to an overall  increase in sales. Furthermore, sales of Vesicare and the candin-type  antifungal agent MyCAMINE grew. Sales of Prograf, Harnal  and prostate cancer treatment Eligard increased mainly  due to the foreign exchange rate impact. Sales in Japan including revenues related to exports and  licenses decreased 1.1% year on year, to ¥530.6 billion.  Sales in the Japanese market rose by 0.2% from the previ- ous fiscal year to ¥515.6 billion. Although there was an  impact of generics, sales remained largely unchanged in  fiscal 2013 from the previous year due to steady expansion  in sales of growing mainstay products and new products. In addition to Betanis, products such as Micardis  (including its combination drugs, Micombi and Micamlo) for  the treatment of hypertension, Celecox, an anti-inflammatory  and anti-pain drug, Symbicort for the treatment of bronchial  asthma, Bonoteo for the treatment of osteoporosis and  vaccines showed growth in sales. There were also contri- butions from sales of new products including Cimzia for the  treatment of adult patients with rheumatoid arthritis and  Gonax for the treatment of prostate cancer. Sales of some  products declined, including Lipitor for the treatment of  hypercholesterolemia, Seroquel for the treatment of schizo- phrenia, Myslee for the treatment of insomnia and Gaster  for the treatment of peptic ulcer and gastritis, mainly due to  the impact of generics. Micamlo BP (combination drug) for  the treatment of hypertension and Acofide for the treatment  of functional dyspepsia were launched in May and June  2013, respectively. Bisono Tape, a transdermal hyperten- sion medication, was launched in September 2013. In Asia and Oceania, sales rose 35.0% year on year, to  ¥58.0 billion. On a basis excluding the impact of foreign  exchange, sales increased 10.9% from the previous year.  Sales expansion of Prograf, Harnal and Vesicare, led to the  increase in revenues. * In sales by product, sales of each product and year-on-year changes are based  on Japanese accounting standards. Sales in Japan increased by 2.0% to ¥50.4 billion. Sales of  the once-daily formulation Graceptor increased steadily.  Outside the transplantation area in Japan, Prograf has  autoimmune disease indications including rheumatoid  arthritis, lupus nephritis, myasthenia gravis, and ulcerative  colitis. Its generics were launched in Japan in June 2013.  The share of generic products in the tacrolimus market,  which includes Prograf and its generics, was approximately  8% during fiscal 2013. Sales in the Americas on a U.S. dollar basis decreased  by 21.9%, to US$296 million, in fiscal 2013 due to the  impact of generic versions. When converted to yen, sales  decreased by 5.8%, to ¥29.6 billion. In August 2013, the  Sales in the Americas increased 38.3% year on year, to  ¥287.0 billion. On a U.S. dollar basis, sales grew 14.6%, to  US$2,863 million. Sales of XTANDI and Myrbetriq, launched in the U.S. in  September and October 2012 respectively, contributed to  Financial Section Annual Report 2014 _  Astellas Pharma Inc.  87 Americas (Sales in North America and Central and South America) Sales of Global Products Sales by Product Europe, Middle East and Africa (EMEA) Japan Note: Sales by geographical area are calculated according to the location of sellers. Asia and Oceania Prograf, Advagraf/  Graceptor/ASTAGRAF (Immunosuppressant) (¥ billion) 2013.3 2014.3 Consolidated ¥981.9 ¥1,139.9 Japan 536.5 530.6 Americas 207.6 287.0 EMEA 194.9 264.3 Asia & Oceania 42.9 58.0 Sales by Geographical Area Sales in EMEA rose 35.6% year on year, to ¥264.3 billion.  On a euro basis, sales also rose 8.1%, to  € 1,967 million.